Cargando…
Efficacy of tocilizumab treatment in severely ill COVID-19 patients
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450680/ https://www.ncbi.nlm.nih.gov/pubmed/32854738 http://dx.doi.org/10.1186/s13054-020-03224-7 |
| _version_ | 1783574852029906944 |
|---|---|
| author | Zhao, Jie Cui, Wei Tian, Bao-ping |
| author_facet | Zhao, Jie Cui, Wei Tian, Bao-ping |
| author_sort | Zhao, Jie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7450680 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74506802020-08-27 Efficacy of tocilizumab treatment in severely ill COVID-19 patients Zhao, Jie Cui, Wei Tian, Bao-ping Crit Care Research Letter BioMed Central 2020-08-27 /pmc/articles/PMC7450680/ /pubmed/32854738 http://dx.doi.org/10.1186/s13054-020-03224-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Research Letter Zhao, Jie Cui, Wei Tian, Bao-ping Efficacy of tocilizumab treatment in severely ill COVID-19 patients |
| title | Efficacy of tocilizumab treatment in severely ill COVID-19 patients |
| title_full | Efficacy of tocilizumab treatment in severely ill COVID-19 patients |
| title_fullStr | Efficacy of tocilizumab treatment in severely ill COVID-19 patients |
| title_full_unstemmed | Efficacy of tocilizumab treatment in severely ill COVID-19 patients |
| title_short | Efficacy of tocilizumab treatment in severely ill COVID-19 patients |
| title_sort | efficacy of tocilizumab treatment in severely ill covid-19 patients |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450680/ https://www.ncbi.nlm.nih.gov/pubmed/32854738 http://dx.doi.org/10.1186/s13054-020-03224-7 |
| work_keys_str_mv | AT zhaojie efficacyoftocilizumabtreatmentinseverelyillcovid19patients AT cuiwei efficacyoftocilizumabtreatmentinseverelyillcovid19patients AT tianbaoping efficacyoftocilizumabtreatmentinseverelyillcovid19patients |